Online citations, reference lists, and bibliographies.
← Back to Search

What Are The Current Best Immunohistochemical Markers For The Diagnosis Of Epithelioid Mesothelioma? A Review And Update.

N. Ordóñez
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Numerous immunohistochemical markers that can assist in the diagnosis of epithelioid mesotheliomas, some of which have only recently been recognized, are currently available. Because the various types of carcinomas express these markers differently, their selection for inclusion in a diagnostic panel can vary according to the differential diagnosis. This article provides a critical review of all of the information that is presently available on those markers that are believed to have the greatest potential for assisting in distinguishing between epithelioid mesotheliomas and those carcinomas with which they are most likely to be confused. Information is also provided regarding the panels of immunohistochemical markers that are, at present, recommended in these differential diagnoses.
This paper references
10.1097/00022744-200206000-00014
Diagnostic Use of Muscle Markers in the Cytologic Evaluation of Serous Fluids
A. Afify (2002)
10.1016/0090-8258(87)90065-5
Lewis and related tumor-associated determinants on ovarian carcinoma.
N. Ordóñez (1987)
10.1053/J.HUMPATH.2003.07.002
Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Chin-Chen Pan (2003)
Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases.
A. Vortmeyer (1991)
10.1097/00000478-199712000-00002
The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
N. Ordóñez (1997)
10.1136/jcp.37.11.1215
Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium.
R. J. Marshall (1984)
10.1097/00000478-199810000-00005
Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
N. Ordóñez (1998)
Les mésothéliomes malins de la plèvre
M. Gross-Goupil (1999)
10.1097/00000478-200302000-00002
Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura
M. Miettinen (2003)
10.1309/XL6K-8E62-9FLD-V8Q8
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
F. Roberts (2001)
10.1016/0046-8177(89)90202-5
Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
M. Noguchi (1989)
10.1016/0046-8177(94)90243-7
Desmin and neural marker expression in mesothelial cells and mesotheliomas.
J. Hurlimann (1994)
10.1111/j.1365-2559.1986.tb02571.x
Secretory component in pulmonary adenocarcinoma and mesothelioma
A. Kondi-Paphitis (1986)
Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
I. Lee (1986)
10.1136/jcp.43.3.213
Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.
U. Latza (1990)
10.1097/00000478-200111000-00008
The Role of Desmin and N-Cadherin in Effusion Cytology: A Comparative Study Using Established Markers of Mesothelial and Epithelial Cells
B. Davidson (2001)
10.1309/21TW-2NDG-JRK4-PFJX
Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.
O. Kaufmann (2001)
10.1002/1097-0142(197909)44:3<937::AID-CNCR2820440322>3.0.CO;2-K
Absence of carcinoembryonic antigen‐like material in mesothelioma An immunohistochemical differentiation from other lung cancers
N. Wang (1979)
10.1097/00000478-200311000-00003
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)
10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z
WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS
S. Kumar-Singh (1997)
10.1111/j.1365-2559.2004.01787.x
WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma
M. Al-Hussaini (2004)
Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues.
F. Momburg (1987)
10.1053/S0046-8177(03)00339-3
Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples.
A. Lugli (2003)
10.1038/modpathol.3880483
Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
P. Chu (2002)
10.1309/8X4T-35B7-7529-QE7X
WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms.
N. Goldstein (2001)
10.1038/modpathol.3880018
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
10.1016/0046-8177(95)90302-X
The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
A. Peralta Soler (1995)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
10.1046/J.1365-2559.2002.01527.X
The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
M. Osborn (2002)
10.1038/sj.bjc.6690393
Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours
A. Marks (1999)
10.1046/j.1365-2559.1996.d01-562.x
Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME‐1 expression
A. Bateman (1997)
10.1046/j.1365-2559.2003.01661.x
Immunohistochemical panel for distinction between squamous cell carcinoma, adenocarcinoma and mesothelioma
S. Pritchard (2003)
10.1016/s0169-5002(87)80458-0
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
K. Sheibani (1986)
10.1053/HUPA.2002.128248
Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers.
N. Ordóñez (2002)
10.1097/01.MP.0000028572.44247.CF
Expression of Thyroid Transcription Factor-1 in Normal and Neoplastic Lung Tissues
N. Nakamura (2002)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
10.1016/J.HUMPATH.2005.08.008
Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
N. Ordóñez (2005)
10.1002/(SICI)1097-0339(199806)18:6<473::AID-DC19>3.0.CO;2-E
Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: Disappointing results in cytology material
A. Filie (1998)
10.1165/AJRCMB.19.1.2953
Evidence against a role of mouse, rat, and two cloned human t1alpha isoforms as a water channel or a regulator of aquaporin-type water channels.
T. Ma (1998)
10.1038/modpathol.3800251
Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach
H. Zhang (2005)
10.1016/S0046-8177(03)00285-5
Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma.
N. Ordóñez (2003)
10.1097/00004347-198909000-00001
Serous Papillary Carcinomas Arising from the Peritoneum and Ovaries. A Clinicopathologic and Immunohistochemical Comparison
M. Wick (1989)
10.1158/1078-0432.CCR-03-0801
Mesothelin: a new target for immunotherapy.
R. Hassan (2004)
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.
K. Chang (1992)
10.1002/IJC.2910380503
Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI
N. Spurr (1986)
Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.
D. Jordon (1989)
Wilms' tumor suppressor gene expression in rat and human mesothelioma.
C. Walker (1994)
10.1111/j.1365-2559.1996.tb01393.x
Mesothelioma‐binding antibodies: thrombomodulin, OV 632 and HBME‐1 and their use in the diagnosis of malignant mesothelioma
R. Attanoos (1996)
10.1046/j.1365-2559.2000.00801.x
Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B
Kaufmann (2000)
10.1046/j.1365-2559.2000.00770.x
HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma
Oates (2000)
10.1083/JCB.125.2.437
Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule
S. Litvinov (1994)
10.1136/jcp.48.7.626
OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
C. Edwards (1995)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
10.1002/1097-0142(19950801)76:3<429::AID-CNCR2820760313>3.0.CO;2-8
Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study
J. Zhou (1995)
10.1002/1097-0142(19850415)55:8<1679::AID-CNCR2820550812>3.0.CO;2-C
Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach
H. Battifora (1985)
10.1002/PATH.1711630406
The differential diagnosis of epithelial‐type mesothelioma from adenocarcinoma and reactive mesothelial proliferation
G. Soosay (1991)
10.1136/jcp.55.9.662
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies
A. S. Abutaily (2002)
10.1111/j.1440-1827.2005.01791.x
Podoplanin as a marker for mesothelioma
Noriko Kimura (2005)
10.1002/PATH.1711650209
Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma
M. Delahaye (1991)
10.1016/S0046-8177(99)90096-5
Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma.
A. Khoór (1999)
10.1159/000086952
Enhanced Expression of Aggrus (T1alpha/Podoplanin), a Platelet-Aggregation-Inducing Factor in Lung Squamous Cell Carcinoma
Y. Kato (2005)
10.1016/S0046-8177(87)80274-5
Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases.
M. Wick (1987)
10.1097/00125480-200007020-00007
Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas.
N. Ordóñez (2000)
10.1002/DC.2840110309
Markers for metastatic adenocarcinoma in serous effusion specimens
P. Shield (1994)
10.1016/0046-8177(90)90050-F
A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
N. Khoury (1990)
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.
C. L. Collins (1992)
10.1128/MCB.13.3.1507
Retroposition in a family of carcinoma-associated antigen genes.
A. Linnenbach (1993)
Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis.
S. Breiteneder-Geleff (1997)
10.1016/S0046-8177(98)90227-1
Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
10.1159/000333181
Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
M. Barberis (1997)
10.1016/0277-5379(84)90043-9
Immunoperoxidase staining on frozen tissue sections as a first screening assay in the preparation of monoclonal antibodies directed against small cell carcinoma of the lung.
L. de Leij (1984)
[Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
M. Chenard-Neu (1990)
10.1016/S0046-8177(97)90171-4
Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
A. Han (1997)
[Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
M. Chenard-Neu (1998)
10.1007/BF01606427
Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: immunohistochemical findings
H. Moch (2005)
10.1309/QHCA-8594-TA7P-0DVQ
An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
U. Brockstedt (2000)
10.1046/j.1365-2559.2001.01157.x
Combined use of novel epithelial (MOC‐31) and mesothelial (HBME‐1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura
C. González-Lois (2001)
10.1097/00022744-199803000-00003
Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias
A. Afify (1998)
10.1007/s00428-003-0859-2
Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray
J. Reis-Filho (2003)
10.1097/00000478-198908000-00004
Peritoneal Malignant Mesothelioma versus Serous Papillary Adenocarcinoma: A Histochemical and Immunohistochemical Comparison
D. Bollinger (1989)
10.1097/00000478-200110000-00010
Metanephric Adenoma, Nephrogenic Rests, and Wilms' Tumor: A Histologic and Immunophenotypic Comparison
T. Muir (2001)
10.1016/S1097-2765(00)80275-0
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.
A. Yang (1998)
10.1097/00000478-200101000-00004
Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis
R. Carella (2001)
10.1016/J.LUNGCAN.2003.10.008
The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms.
Y. Chang (2004)
10.1002/1097-0142(19931015)72:8<2495::AID-CNCR2820720830>3.0.CO;2-E
Reactivity of b72.3 with adenocarcinomas. An immunohistochemical study of 476 cases
T. S. Loy (1993)
10.1046/j.1365-2559.1997.6020829.x
Value of thrombomodulin immunostaining in the diagnosis of mesothelioma
N. Ordóñez (1997)
10.1097/00000478-200002000-00006
Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms.
A. Avery (2000)
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
K. Amin (1995)
10.1007/BF02981468
Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3—A new tumor marker
C. Kortsik (2008)
10.1038/modpathol.3800259
Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma
Albert Y Chu (2005)
10.1097/01.pgp.0000092130.10100.88
Wilms Tumor Gene Immunoreactivity in Primary Serous Carcinomas of the Fallopian Tube, Ovary, Endometrium, and Peritoneum
A. Hashi (2003)
10.1007/BF00713385
Immunohistochemistry in the diagnosis of malignant mesothelioma
M. Pfaltz (2004)
10.1093/AJCP/109.1.85
Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
N. Ordóñez (1998)
10.1097/00000478-199203000-00006
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.
J. Magnani (1983)
10.1016/S0002-9440(10)62311-5
Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors.
V. Schacht (2005)
10.1309/K84K-005F-TCB8-FV4B
WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.
N. Goldstein (2002)
10.1309/LWP3-MFA8-8KX7-60YQ
Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinoma.
A. López-Ferrer (2002)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1046/j.1365-2559.1998.00349.x
E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
Leers (1998)
10.1093/emboj/cdg342
T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema
V. Schacht (2003)
10.1038/BJC.1987.276
Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker.
G. Moldenhauer (1987)
10.1053/HUPA.2000.9076
Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas.
M. Lyda (2000)
10.1159/000333982
Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
M. E. Bailey (1996)
10.1002/DC.2840060104
“Thick” cell membranes revealed by immunocytochemical staining: A clue to the diagnosis of mesothelioma
A. Leong (1990)
Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas.
S. Yoshida (1989)
10.1309/8FCHQ3VPBWM7B5X9
Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful.
R. Barnetson (2006)
10.1016/0046-8177(93)90080-Z
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
R. Brown (1993)
The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.
G. Blobel (1985)
10.1097/00129039-200409000-00010
p63 Expression in Lung Carcinoma: A Tissue Microarray Study of 408 Cases
N. Au (2004)
10.1002/1097-0142(19910201)67:3<655::AID-CNCR2820670322>3.0.CO;2-J
Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma
P. R. Wirth (1991)
10.1097/00000478-199206000-00007
Immunoreactivity for BER‐EP4 in Adenocarcinomas, Adenomatoid Tumors, and Malignant Mesotheliomas
M. Gaffey (1992)
10.1097/00000478-200105000-00007
Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma
M. Miettinen (2001)
10.1097/00000478-200004000-00016
Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
N. Ordóñez (2000)
10.1038/modpathol.3880386
Parvalbumin Is Constantly Expressed in Chromophobe Renal Carcinoma
G. Martignoni (2001)
10.1043/0003-9985(2001)125<1316:IAONVC>2.0.CO;2
Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas.
M. Foster (2001)
10.1097/00000478-199108000-00008
Ber‐EP4 Antibody as a Discriminant in the Differential Diagnosis of Malignant Mesothelioma Versus Adenocarcinoma
K. Sheibani (1991)
10.1016/8756-3282(95)00457-2
Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes.
A. Wetterwald (1996)
10.1002/DC.2840120119
Ov632 as a possible marker for malignant mesothelioma: High expectations; Low specificity
A. Abati (1995)
10.1016/0046-8177(90)90036-5
Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.
M. Wick (1990)
Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.
M. Warnock (1988)
10.1097/00000478-200112000-00003
Diagnosing Primary and Metastatic Renal Cell Carcinoma: The Use of the Monoclonal Antibody `Renal Cell Carcinoma Marker'
D. K. McGregor (2001)
10.1097/00000478-199712000-00003
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
10.1097/00000478-198505000-00006
Immunohistochemical staining for vimentin and keratin in malignant mesothelioma
A. Churg (1985)
10.1097/00000478-198904000-00003
The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (1989)
Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
T. Ruitenbeek (1994)
[Cell marker for the differential diagnosis of malignant mesotheliomas].
J. Hastka (1988)
10.1016/J.HUMPATH.2003.11.013
The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
N. Ordóñez (2004)
10.1046/j.1365-2559.2002.01352.x
Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum
R. Attanoos (2002)
10.1038/modpathol.3800544
The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study
N. Ordóñez (2006)
10.1016/J.HUMPATH.2004.11.011
The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors.
H. Cathro (2005)
10.1111/J.1699-0463.1985.TB03940.X
S-100 protein in malignant mesotheliomas.
O. Rasmussen (1985)
10.1016/S0002-9440(10)65285-6
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium.
S. Breiteneder-Geleff (1999)
10.1016/S0002-9440(10)63570-5
The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology.
M. J. Winter (2003)
The diagnostic value of thrombomodulin immunolocalization in serous effusions.
V. Ascoli (1995)
10.1038/modpathol.3880543
Monoclonal Antibody D2-40, a New Marker of Lymphatic Endothelium, Reacts with Kaposi's Sarcoma and a Subset of Angiosarcomas
H. Kahn (2002)
10.1016/J.HUMPATH.2005.01.019
D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
N. Ordóñez (2005)
10.1046/j.1365-2559.1997.2150833.x
Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma
J. Clover (1997)
10.1111/j.1365-2559.1992.tb00430.x
Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon
F. Mayall (1992)
10.1046/j.1365-2559.1997.d01-590.x
CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma
R. Attanoos (1997)
10.1053/HUPA.2001.24329
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
C. Comin (2001)
The value of epithelial membrane antigen in the diagnosis of ovarian tumors.
Ikuno Fujimoto (1990)
Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation.
Y. Sugimoto (1991)
10.1016/S0344-0338(96)80208-1
The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.
V. Gotzos (1996)
10.1097/01.MP.0000056981.16578.C3
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
N. Ordóñez (2003)
10.1038/modpathol.3800471
The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study
N. Ordóñez (2006)
10.1016/0046-8177(90)90081-F
Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases.
L. Truong (1990)
Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies.
M. Watanabe (1988)
10.1136/thx.40.2.91
Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma.
A. Gibbs (1985)
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)
10.1002/dvdy.10163
Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate
Young-Kwon Hong (2002)
10.1046/j.1365-2559.1998.00405.x
A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours
Garcia‐Prats (1998)



This paper is referenced by
10.1111/j.1365-2303.2010.00757.x
PINCH‐2 expression in cancers involving serosal effusions using quantitative PCR
Y. Yuan (2011)
10.4415/ANN_15_01_09
Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines.
V. Ascoli (2015)
10.1007/978-3-030-30766-0_36
Occupational Cancer in the Practice of Occupational Medicine
E. Pira (2020)
10.1111/his.13073
Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma
K. Kushitani (2017)
10.1007/978-1-4419-0489-8_14
Surface Epithelial Tumors of the Ovary
J. Seidman (2011)
10.1111/vcp.12898
What is your diagnosis? Pericaridal mass in a 12-year-old dog.
Brandy C Kastl (2020)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
10.1002/dc.21398
Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations
K. Ikeda (2011)
10.1111/j.1365-2559.2009.03322.x
Caveolin‐1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma
V. Amatya (2009)
10.1016/j.athoracsur.2017.06.042
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
B. Burt (2017)
Multiparameter flow cytometric immunophenotyping of epithelial cells in effusions. Technical improvements and apoptosis measurement.
H. Dong (2013)
10.1586/14737140.7.1.31
Adult human sarcomas. I. Basic science
J. Sinkovics (2007)
10.1016/B978-1-4160-5329-3.00004-9
Chapter 4 – Pleural, Pericardial, and Peritoneal Fluids
E. Cibas (2009)
10.4021/jocmr2009.05.1241
Localized Malignant Myxoid Anaplastic Mesothelioma of the Pericardium
G. Yang (2009)
10.1007/s00292-014-1922-2
[Pleural mesothelioma. Cytology and molecular diagnostics].
Tatjana Vlajnic (2014)
10.1007/s00428-007-0448-x
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions
F. Facchetti (2007)
10.1002/cncy.21302
Endosalpingiosis in peritoneal washings in women with benign gynecologic conditions
N. Sneige (2013)
10.1002/cncr.23413
9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA‐ICM, and AgNOR analysis
F. Onofre (2008)
10.1159/000114542
Xanthomatous Pleuritis Mimicking Mesothelioma
Franklin R. McGuire (2008)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology
R. Martins (2012)
10.1186/1749-8090-8-50
Primary pleural squamous cell carcinoma misdiagnosed as localized mesothelioma: a case report and review of the literature
Xiao-Ming Lin (2013)
10.1097/PAS.0b013e3181452176
Calretinin Expression in the Differential Diagnosis of Human Ameloblastoma and Keratocystic Odontogenic Tumor
P. Devilliers (2008)
10.1007/978-981-15-3773-8
Pathology of Peritoneal Metastases: The Unchartered Fields
Olivier Gléhen (2020)
10.1016/j.ctrv.2015.05.001
The established and future biomarkers of malignant pleural mesothelioma.
V. Panou (2015)
10.1097/PAS.0b013e3181b6bde3
Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
Y. Yuan (2009)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.1111/j.1365-2559.2008.03178.x
Problems in mesothelioma diagnosis
Bruce Addis (2009)
10.1007/978-1-4419-9751-7
Diagnostic Pathology of Ovarian Tumors
R. Soslow (2011)
10.1002/dc.21563
Tumor type and single‐cell/mesothelial‐like cell pattern of breast carcinoma metastases in pleural and peritoneal effusions
T. Antic (2012)
10.2147/OTT.S145105
Amatuximab and novel agents targeting mesothelin for solid tumors
P. Baldo (2017)
10.1007/978-3-030-16884-1_8
Tissue and Circulating Biomarkers in Mesothelioma
Paolo Andrea Zucali (2019)
10.1159/000127577
Mesothelioma and Asbestos-Related Pleural Diseases
L. Greillier (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar